Here are the 10-Q quarterly reports from Inspire Veterinary Partners, Inc. (IVP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IVP filings page.
Inspire Veterinary Partners (IVP) filed its Q3 2025 10‑Q, reporting quarterly revenue of $4,316,132, up modestly from $4,049,025 a year ago. The company posted a net loss of $2,526,273 for the quarter, improving from a $3,489,326 loss last year. For the nine months, revenue was $12,238,875 versus $13,270,973, with a net loss of $7,975,878 versus $10,297,539.
Total assets rose to $23,955,766 from $20,195,994, and stockholders’ equity increased to $4,168,681 from $1,562,005, aided by new financing. Cash used in operations was $3,555,276 year‑to‑date; cash, cash equivalents and restricted cash ended at $576,246. Interest expense was $559,111 in Q3 and $1,385,891 year‑to‑date.
The company disclosed “substantial doubt” about its ability to continue as a going concern due to recurring losses, an accumulated deficit of $44,326,158, and negative working capital of $5,894,301 as of September 30, 2025. IVP completed private placements of Series B preferred stock in July and September for approximately $6 million combined and recognized a $2,571,429 investment in equity securities. Nasdaq later confirmed compliance with its minimum stockholders’ equity requirement.